AbCellera Biologics (ABCL) IPO Opens 205% Higher

Today's IPO for AbCellera Biologics Inc. (NASDAQ: ABCL) opened for trading at $61 after pricing its initial public offering of 24,150,000 common shares at a price to the public of $20.00 per share.

In addition, AbCellera has granted the underwriters a 30-day option to purchase up to 3,622,500 additional common shares at the initial public offering price, less underwriting discounts and commissions.

Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets are acting as joint book-running managers for the offering.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development.

You May Also Be Interested In

• OpenAI revenue chief quits after less than a year
• ROC posts $5.1M in Q2 revenue, doubling sequentially on gov't contracts
• Nexon Releases Earnings for Second Quarter 2026